← ANALYST RATINGS · TIPRANKS
Janux Therapeutics Inc (JANX): analyst forecast and price target
Analyst consensus
Strong Buy10 Buy0 Hold1 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $33.40, the highest $60.00, the lowest $14.00. The average is +102.3% from the last price of $16.51.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Supawat Thongthip★★★★★★★★★★#6413 · hits 70% · avg +6.4% | Truist Financial | $26.00 | Buy | +57.5% | Reiterated | 15.10.26on TipRanks 08:31 | +0.8%next day −3.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $19.50 → $19.00−2.6% | Hold | +15.1% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $19.50 → $19.00−2.6% | Hold | +15.1% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $19.00 → $18.50−2.6% | Hold | +12.1% | Reiterated | 13.10.26on TipRanks 06:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $18.50 → $18.00−2.7% | Hold | +9.0% | Reiterated | 11.10.26on TipRanks 05:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $18.50 → $19.50+5.4% | Hold | +18.1% | Reiterated | 09.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.50 → $19.50+5.4% | Hold | +18.1% | Reiterated | 09.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.00 → $19.00+5.6% | Hold | +15.1% | Reiterated | 09.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $17.50 → $18.50+5.7% | Hold | +12.1% | Reiterated | 09.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $18.00 → $19.00+5.6% | Hold | +15.1% | Reiterated | 09.10.26on TipRanks 05:06 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $45.00 | Buy | +172.6% | Reiterated | 01.10.26on TipRanks 10:35 | −2.0%next day −0.9% · 5 days +7.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $18.50 | Hold | +12.1% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $18.50 | Hold | +12.1% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.00 | Hold | +9.0% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $17.50 | Hold | +6.0% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $18.50 → $18.00−2.7% | Hold | +9.0% | Reiterated | 23.09.26on TipRanks 06:07 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $21.00 → $20.50−2.4% | Hold | +24.2% | Reiterated | 09.09.26on TipRanks 07:05 | — | |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | $23.00 | Buy | +39.3% | Upgrade | 24.08.26on TipRanks 06:25 | +7.3%next day +0.1% · 5 days −2.5% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 13.08.26on TipRanks 18:25 | +0.9%next day +1.3% · 5 days +9.2% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $35.00 | Buy | +112.0% | Reiterated | 11.08.26on TipRanks Aug 12 22:05 | +1.0%next day +0.7% · 5 days +3.1% | ↗ |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $45.00 | Buy | +172.6% | Reiterated | 10.08.26on TipRanks 06:30 | +3.6%next day +1.0% · 5 days −0.9% | ↗ |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | $60.00 | Buy | +263.4% | Reiterated | 07.08.26on TipRanks 14:35 | −2.2%next day +3.6% · 5 days +1.3% | ↗ |
| Supawat Thongthip★★★★★★★★★★#6413 · hits 70% · avg +6.4% | Truist Financial | — | Buy | — | Reiterated | 07.08.26on TipRanks 11:25 | −2.2%next day +3.6% · 5 days +1.3% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $26.00 | Buy | +57.5% | Reiterated | 07.08.26on TipRanks 08:00 | −2.2%next day +3.6% · 5 days +1.3% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $28.00 | Buy | +69.6% | Reiterated | 07.08.26on TipRanks 07:45 | −2.2%next day +3.6% · 5 days +1.3% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $21.00 → $22.00+4.8% | Buy | +33.3% | Reiterated | 07.08.26on TipRanks 06:50 | −2.2%next day +3.6% · 5 days +1.3% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $14.00 | Sell | −15.2% | Reiterated | 07.08.26on TipRanks 04:19 | −2.2%next day +3.6% · 5 days +1.3% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $58.00 → $55.00−5.2% | Buy | +233.1% | Assigned | 06.08.26on TipRanks Aug 7 07:45 | +0.8%next day −2.2% · 5 days −1.8% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $23.00 → $22.00−4.3% | Buy | +33.3% | Reiterated | 11.05.26on TipRanks 08:15 | +0.2%next day +1.4% · 5 days −1.3% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $45.00 → $36.00−20.0% | Buy | +118.0% | Reiterated | 08.05.26on TipRanks 09:50 | −3.3%next day +0.2% · 5 days −2.2% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 08.05.26on TipRanks 01:08 | −3.3%next day +0.2% · 5 days −2.2% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $57.00 → $15.00−73.7% | Hold | −9.1% | Downgrade | 15.04.26on TipRanks 05:25 | −2.1%next day +0.8% · 5 days +0.7% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $150 → $100−33.3% | Buy | +505.7% | Reiterated | 26.02.26on TipRanks Feb 27 09:20 | +1.3%next day −0.9% · 5 days +2.4% | ↗ |
| Justin Zelin★★★★★★★★★★#4442 · hits 36% · avg +3.1% | BTIG | $100 | Buy | +505.7% | Reiterated | 22.01.26on TipRanks Jan 23 06:55 | +13.6%next day −2.2% · 5 days −9.4% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $32.00 → $12.00−62.5% | Hold | −27.3% | Downgrade | 20.01.26on TipRanks 05:25 | −2.4%next day −0.2% · 5 days +9.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Janux Therapeutics Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $34.22 at a price of $17.28 (+98.0%); now: $33.40 at $16.51 (+102.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 17 | 8 | 8 | 7 | 9 |
| Buy | 5 | 5 | 3 | 5 | 5 | 5 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 2 | 2 | 1 | 1 | 1 | 1 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.47 (from $-0.67 to $-0.04). Last quarter: $-0.35.
Sales
Next quarter’s sales estimate — $8M (from $0M to $35M). Last quarter: $10M.
Best top-analyst consensus in the sector · Healthcare
About Janux Therapeutics Inc
- CEO: David Alan Campbell
- Employees: 113
- 10955 Vista Sorrento Parkway, San Diego, CA, 92130, US
- www.januxrx.com
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Data from the stock’s TipRanks forecast page, read 52 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗